Platelet function testing in contemporary clinical and interventional practice. (Q51746988)

11 April 2018

title

Platelet function testing in contemporary clinical and interventional practice. (English)

1 reference

11 April 2018

5

Dominick J Angiolillo

1 reference

11 April 2018

author name string

Francesco Franchi

1

1 reference

11 April 2018

Fabiana Rollini

2

1 reference

11 April 2018

Jung Rae Cho

3

1 reference

11 April 2018

Elisabetta Ferrante

4

1 reference

11 April 2018

publication date

1 May 2014

1 reference

11 April 2018

Current treatment options in cardiovascular medicine

published in

1 reference

11 April 2018

volume

16

1 reference

11 April 2018

issue

5

1 reference

11 April 2018

page(s)

300

1 reference

11 April 2018

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Aspirin resistance: Fact or fiction? A point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Clopidogrel-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Switching acute coronary syndrome patients from prasugrel to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

2013 ESC guidelines on the management of stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Impact of Gastric Acid–Suppressing Therapies on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0300-Y

Switching from prasugrel to clopidogrel: navigating in unknown waters

21 January 2018

1 reference

12 December 2020

Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study

1 reference

12 December 2020

Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleed

1 reference

12 December 2020

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

12 December 2020

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

1 reference

12 December 2020

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers

1 reference

12 December 2020

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

1 reference

12 December 2020

Platelet Function Measured Using a Whole Blood Aggregometer Can Predict Bleeding Events

1 reference

12 December 2020

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

1 reference

12 December 2020

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

1 reference

12 December 2020

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

12 December 2020

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

1 reference

12 December 2020

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel

1 reference

12 December 2020

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

1 reference

12 December 2020

The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial)

1 reference

12 December 2020

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations

1 reference

12 December 2020

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

1 reference

12 December 2020

10.1007/S11936-014-0300-Y

Identifiers

DOI

1 reference

11 April 2018

1 reference

11 April 2018